COVID’s ‘mysterious 2-month cycle’ may point to its own end

As COVID-19 continues its latest falloff—U.S. and global cases are down by more than 30% over the past five weeks—close observers are trying to unravel the mystery of the virus’s repeating two-month cycles of surges and retreats.

“The most-plausible explanations involve some combination of virus biology and social networks,” New York Times senior writer David Leonhardt writes in Oct. 4 commentary.

It could be that each strain ebbs as it runs out of vulnerable immune systems to infect, or maybe two months is the time it takes an average-sized community to develop group immunity, Leonhardt suggests.

In any case, the uncertainty also means that “the near future could prove to be more encouraging than we expect,” Leonhardt comments. “And there are some legitimate reasons for COVID optimism.”

Among these:

  • More than three-quarters of Americans 12 and up have received at least one shot;
  • The ranks of the vaccinated are likely to continue growing this fall as mandates kick in and a dose for children earns FDA approval; and
  • Something close to half of Americans have natural immunity after contracting and beating COVID.

More:

COVID isn’t going to disappear anytime soon. It will continue to circulate for years, many scientists believe. But the vaccines can transform COVID into a manageable disease, not so different from a flu or common cold. In the past few weeks, the country appears to have moved closer to that less-grim future. … Whatever the next few months bring, the worst of the pandemic is almost certainly behind us.”

Full piece here via Yahoo! News.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”